EP4704832A2 - Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes - Google Patents

Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes

Info

Publication number
EP4704832A2
EP4704832A2 EP24798151.7A EP24798151A EP4704832A2 EP 4704832 A2 EP4704832 A2 EP 4704832A2 EP 24798151 A EP24798151 A EP 24798151A EP 4704832 A2 EP4704832 A2 EP 4704832A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
compound
linker
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24798151.7A
Other languages
German (de)
English (en)
Inventor
Gene M. Dubowchik
Wieslaw Kazmierski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of EP4704832A2 publication Critical patent/EP4704832A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des petites molécules bifonctionnelles qui contiennent une fraction de liaison de protéine circulante (CPBM) liée par l'intermédiaire d'un groupe de liaison à une fraction de liaison de récepteur cellulaire (CRBM) qui est un récepteur membranaire d'une cellule de dégradation tel qu'un hépatocyte ou une autre cellule de dégradation. Dans certains modes de réalisation, la (CPBM) est une fraction qui se lie à l'immunoglobuline G. Dans certains modes de réalisation, la (CRBM) est une fraction qui se lie au récepteur d'asialoglycoprotéine (une fraction de liaison de récepteur d'asialoglycoprotéine, ou ASGPRBM) d'un hépatocyte.
EP24798151.7A 2023-04-28 2024-04-28 Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes Pending EP4704832A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363498852P 2023-04-28 2023-04-28
US202363517984P 2023-08-07 2023-08-07
PCT/US2024/026709 WO2024227119A2 (fr) 2023-04-28 2024-04-28 Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes

Publications (1)

Publication Number Publication Date
EP4704832A2 true EP4704832A2 (fr) 2026-03-11

Family

ID=93257447

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24798151.7A Pending EP4704832A2 (fr) 2023-04-28 2024-04-28 Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes

Country Status (7)

Country Link
EP (1) EP4704832A2 (fr)
KR (1) KR20250172727A (fr)
CN (1) CN121127237A (fr)
AU (1) AU2024264049A1 (fr)
IL (1) IL323835A (fr)
MX (1) MX2025012651A (fr)
WO (1) WO2024227119A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219911A1 (fr) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Traitement de maladies avec médicaments à base d'anticorps monoclonaux et agents de dégradation moléculaires
WO2025248469A1 (fr) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Traitement de maladies liées à l'igg
WO2026028158A1 (fr) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Dégradation ciblée d'anticorps anti-aav pour permettre une thérapie génique à base d'aav

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101525298B1 (ko) * 2012-01-18 2015-06-03 고려대학교 산학협력단 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도
EP3658170A4 (fr) * 2017-07-26 2021-08-25 Kleo Pharmaceuticals, Inc. Composés abt universels et leurs utilisations
EP4334360A2 (fr) * 2021-05-03 2024-03-13 Avilar Therapeutics, Inc. Composés puissants de liaison à l'asgpr permettant la dégradation d'immunoglobulines et d'autres protéines

Also Published As

Publication number Publication date
AU2024264049A1 (en) 2025-11-27
MX2025012651A (es) 2025-11-03
IL323835A (en) 2025-12-01
KR20250172727A (ko) 2025-12-09
CN121127237A (zh) 2025-12-12
WO2024227119A2 (fr) 2024-10-31
WO2024227119A3 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
US20240083859A1 (en) Bi-functional Molecules To Degrade Circulating Proteins
JP7842459B2 (ja) ターゲティングされた二官能性分解剤
US20250332274A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
WO2024227119A2 (fr) Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes
CN118103075A (zh) 双环肽毒素偶联物及其中间体的合成
US12485178B2 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
US20250205343A1 (en) Bi-functional molecules to degrade circulating proteins
WO2023178202A2 (fr) Petites molécules bifonctionnelles pour le ciblage de la dégradation sélective de protéines circulantes
CN113603675A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
CN119212726A (zh) 降解循环蛋白的双功能分子
JP2026515874A (ja) 循環タンパク質の選択的分解を標的とする二官能性小分子
AU2015289178A1 (en) Novel compounds
HK40042237A (en) Bifunctional small molecules to target the selective degradation of circulating proteins
TW201109335A (en) Heterocyclic compounds
HK1262126B (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
HK1262126A1 (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR